| Literature DB >> 33691136 |
Shin-Heng Chiou1, Diane Tseng2, Alexandre Reuben3, Vamsee Mallajosyula1, Irene S Molina1, Stephanie Conley4, Julie Wilhelmy5, Alana M McSween1, Xinbo Yang6, Daisuke Nishimiya6, Rahul Sinha4, Barzin Y Nabet7, Chunlin Wang1, Joseph B Shrager8, Mark F Berry9, Leah Backhus8, Natalie S Lui8, Heather A Wakelee10, Joel W Neal10, Sukhmani K Padda2, Gerald J Berry11, Alberto Delaidelli12, Poul H Sorensen12, Elena Sotillo13, Patrick Tran13, Jalen A Benson9, Rebecca Richards14, Louai Labanieh15, Dorota D Klysz13, David M Louis1, Steven A Feldman13, Maximilian Diehn16, Irving L Weissman4, Jianjun Zhang17, Ignacio I Wistuba18, P Andrew Futreal19, John V Heymach3, K Christopher Garcia20, Crystal L Mackall21, Mark M Davis22.
Abstract
To identify disease-relevant T cell receptors (TCRs) with shared antigen specificity, we analyzed 778,938 TCRβ chain sequences from 178 non-small cell lung cancer patients using the GLIPH2 (grouping of lymphocyte interactions with paratope hotspots 2) algorithm. We identified over 66,000 shared specificity groups, of which 435 were clonally expanded and enriched in tumors compared to adjacent lung. The antigenic epitopes of one such tumor-enriched specificity group were identified using a yeast peptide-HLA A∗02:01 display library. These included a peptide from the epithelial protein TMEM161A, which is overexpressed in tumors and cross-reactive epitopes from Epstein-Barr virus and E. coli. Our findings suggest that this cross-reactivity may underlie the presence of virus-specific T cells in tumor infiltrates and that pathogen cross-reactivity may be a feature of multiple cancers. The approach and analytical pipelines generated in this work, as well as the specificity groups defined here, present a resource for understanding the T cell response in cancer.Entities:
Keywords: EBV; EntS; GLIPH2; LMP2A; NSCLC; T cell receptor repertoire; T cell specificity; TCR; TMEM161A; cancer; cross-reactivity; tumor-infiltrating lymphocyte
Year: 2021 PMID: 33691136 DOI: 10.1016/j.immuni.2021.02.014
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745